Document is current
Any future updates will be listed below
-
Authors
Mauricaite, Radvile
Calvez, Kerlann Le
Robinson, Stephen David
Camp, Sophie
Brodbelt, Andrew
Booth, Thomas C.
Williams, Matt https://orcid.org/0000-0001-7096-0718
-
Funding
Funding for this research was provided by:
University Hospitals Sussex NHS Foundation Trust Medical Doctoral Fellowship
Wellcome Trust (WT 203148/Z/16/Z)
Imperial College Healthcare NHS Trust
Imperial College London
NIHR Imperial Biomedical Research Centre
Brain Tumour Research
- License Information
-
More Information
Article History
Received: 30 October 2025
Accepted: 20 January 2026
First Online: 25 April 2026
Declarations
:
: Research ethics approval was granted by the Yorkshire and the Humber – Sheffield Research Ethics Committee (REC reference: 16/YH/0213). This study was performed in line with the principles of the Declaration of Helsinki. All published data are anonymised and non-identifiable.
: Not applicable.
: This data uses anonymised pooled data from multiple national datasets. In line with published guidance, such work does not require individual informed patient consent. All published data are anonymised and non-identifiable. There is a data-sharing agreement (DSA) in place between NHS England/Digital and our team (“Computational Oncology Laboratory” hosted at Imperial College London) that specifies that we’re allowed to publish aggregated patients’ data in peer-reviewed journals. Further to the DSA, we also have Research Ethics Committee (REC) approvals that gave us permission to publish aggregated patients’ data in peer-reviewed journals. Finally, and further to the DSA and REC approvals, we’re using routinely-collected data captured by NHS England, which uses the legal basis of Articles 6(1)(c) and 9(2)(g) of the UK GDPR.
: MW holds share options and salary from Ourotech. Has had hospitality from Novocure.President of British Radiosurgery Society
